Statement: 0 patients in the primary trial or the secondary trial died.
Primary_evidence: Adverse Events 1:   Total: 18/70 (25.71%)   Cardiac arrest  1/70 (1.43%)   Pericardial effusion  1/70 (1.43%)   Ear pain  1/70 (1.43%)   Blurred vision  1/70 (1.43%)   Eye disorders - Other, specify  2/70 (2.86%)   Abdominal Pain  5/70 (7.14%)   Colitis  1/70 (1.43%)   Diarrhea  2/70 (2.86%)   Nausea  2/70 (2.86%)   Death NOS  1/70 (1.43%)   Edema limbs  1/70 (1.43%)   Fatigue  3/70 (4.29%)
Secondary_evidence: Adverse Events 1:   Total: 5/261 (1.92%)   Cholecystitis chronic 1/261 (0.38%)   Post procedural bile leak 1/261 (0.38%)   Spinal column stenosis 1/261 (0.38%)   Depression 1/261 (0.38%)   Mania 1/261 (0.38%)   Pulmonary embolism 1/261 (0.38%)